Welcome to the e-CCO Library Archive!
The effects of anti TNF therapy on growth in Scottish children with IBD
F.L. Cameron1, M. Al Towati2, P. Rogers3, P. McGrogan4, W.M. Bisset5, S.F. Ahmed2, D.C. Wilson1, R.K. Russell4, 1University of Edinburgh, Child Life and Health, Edinburgh, United Kingdom, 2University of Glasgow, Child Health, Glasgow, United Kingdom, 3Royal Hospital for Sick Children, Paediatric Gastroenterology, Edinburgh, United Kingdom, 4Royal Hospital for Sick Children, Paediatric Gastroenterology, Glasgow, United Kingdom, 5Royal Aberdeen Children's Hospital, Department of Paediatric Gastroenterology, Aberdeen, United Kingdom
W.-C. Lim1, W.-K. Ng1, C. Vu1, 1Tan Tock Seng Hospital, Department of Gastroenterology and Hepatology, Singapore, Singapore
Cost per clinical outcomes with biologics for the treatment of moderately to severely active ulcerative colitis
J. Jansen1, R. Mody*2, I. Ursan2, M. Lorenzi1, H. Patel3, M. Alberton1
1Redwood Outcomes, , San Francisco, United States, 2Takeda Pharmaceuticals International, Inc., Global Outcomes Research, Deerfield, United States, 3Immensity Consulting, Inc, , Chicago, United States
The effectiveness of adalimumab maintenance treatment for Crohn's disease and related prognostic factors: a Japanese single-center study
H. Tanaka, M. Miyakawa, M. Nasuno, S. Motoya, A. Imamura, Sapporo Kosei General Hospital, IBD Center, Sapporo, Japan
W. Sandborn1, B. Sands2, P. Rutgeerts3, S. Sankoh4, M. Rosario4, C. Milch4, I. Fox4, 1University of California, San Diego Health System, San Diego, 2Mount Sinai School of Medicine, Division of Gastroenterology, New York, USA, 3University of Leuven, Leuven, Belgium, 4Millennium Pharmaceuticals, Inc., Cambridge, United States
Risk factor analysis for therapy related adverse events and infections in elder patients with Inflammatory Bowel Disease; An analysis from the IG-IBD aged study
A. Ferrara*1, A. Viola1, N. Mannetti2, M. Coppola2, I. Frankovic3, R. Monterubbianesi4, D. Pugliese5, A. Aratri6, M. Cappello7, G. Costantino1, S. Saibeni8, M. Principi9, F. Furfaro10, G. Fiorino11, G. Mocci12, F. Castiglione13, G. Scalisi14, F. Callela15, A. Magarotto16, F. Caprioli16, G. Casella17, L. Samperi18, A.C. Privitera19, G. Inserra18, S. Danese11, S. Ardizzone10, C. Papi6, A. Armuzzi5, 20, A. Kohn4, F. Bossa14, R. D'Incà3, V. Annese2, A. Alibrandi21, W. Fries1
1University of Messina, Dept. of Clinical and Experimental Medicine, Messina, Italy, 2Careggi, University Hospital, Gastroenterology Unit, Firenze, Italy, 3University of Padua, Department of Surgery, Oncology and Gastroenterology, Padua, Italy, 4A.O.San Camillo Forlanini, Gastroenterology Unit, Rome, Italy, 5Catholic University, IBD Unit, Complesso Integrato Columbus, Rome, Italy, 6A.O.San Filippo Neri, Gastroenterology and Hepatology Unit, Rome, Italy, 7A.O.U. Policlinico, UOC Gastroenterologia ed Epatologia, Palermo, Italy, 8AO Fatebenefratelli e Oftalmico, UOC di Medicina Interna ed Epatologia, Milano, Italy, 9University of Bari, Gastroenterology Section (D.E.T.O.), Bari, Italy, 10Luigi Sacco University Hospital, Gastroenterology and IBD Unit, Milan, Italy, 11Humanitas Research Hospital, IBD Center, Dept. of Gastroenterology, Rozzano, Milan, Italy, 12Azienda Ospedaliero Universitaria di Cagliari, Gastroenterology, Cagliari, Italy, 13Seconda Università di Napoli, Gastroenterology, Napoli, Italy, 14IRCCS “Casa Sollievo della Sofferenza”, Div of Gastroenterology, San Giovanni Rotondo (FG), Italy, 15Ospedale San Giuseppe, UOC Gastroenterologia, Empoli (FI), Italy, 16Fondazione IRCCS Cà Granda, Ospedale Maggiore Policlinico, Gastroenterology and Endoscopy Unit, Milan, Italy, 17Ospedale Desio,, Dipartimento di Medicina, Desio (MB), Italy, 18University of Catania, Dip. di Scienze Mediche e Pediatriche, UO Medicina Interna, Catania, Italy, 19Azienda Ospedaliera per l'Emergenza , Gastroenterology, Catania, Italy, 20Catholic University, Rome, Complesso Integrato Columbus, IBD UNIT, Roma, Italy, 21University of Messina, Department of Economical, Financial, Social, Environmental, Statistical and Territorial Sciences, Messina, Italy
The clinical comparative demographic features between inpatient and outpatient of IBD
S. Sadri1, I. Hatemi2, Y. Erzin2, B. Baca3, A.F. Celik2, 1Istanbul University Cerrahpasa Medical Faculty, Internal Medicine, Istanbul, Turkey, 2Istanbul University Cerrahpasa Medical Faculty, Gastroenterology, Istanbul, Turkey, 3Istanbul University Cerrahpasa Medical Faculty, General Surgery, Istanbul, Turkey
M. Rivero1, M.A. Mieses1, I. Moraleja1, A. Fontalva1, B. Castro1, J. Crespo1, 1University Hospital Marques de Valdecilla, Gastroenterology unit, Santander, Spain
Biomarkers predict lack of response to anti-TNF in Moderate to Severe Ulcerative Colitis
J.F. Brandse*1, S. Singh2, M. Löwenberg1, C.Y. Ponsioen1, G.R. van den Brink1, G.R. D'Haens1
1Academic Medical Center, Inflammatory Bowel Disease Center, Amsterdam, Netherlands, 2Prometheus Laboratories, Therapeutics&Diagnostics, San Diego, California, United States
The budgetary impact of 2 g mesalazine for the treatment of mild to moderate ulcerative colitis
I. Lovelace1, E. Tate2, S. Knapp3, J. Masure4, G. Shields2, 1Ferring Pharmaceuticals, UK Medical, West Drayton, United Kingdom, 2BresMed, Health Economics Consulting, Sheffield, United Kingdom, 3Ferring Pharmaceuticals, UK Gastroenterology, West Drayton, United Kingdom, 4Ferring Pharmaceuticals, Global Gastroenterology Department, Saint-Prex, Switzerland
M. Nagahori1, T. Fujii1, E. Saito1, K. Ohtsuka1, M. Watanabe1, 1Tokyo Medical and Dental University, Department of Gastroenterology and Hepatology, Tokyo, Japan
Unfavorable initial thiopurine response does not reduce anti-drug antibody formation compared to thiopurine responders in Crohn's disease patients treated by thiopurine & infliximab co-therapy
H. Bar-Yoseph1, R. Almog2, B. Ungar3, S. Ben-Horin3, H. Yanai4, I. Dotan4, Y. Chowers5, M. Waterman*5
1Rambam Health Care Campus & Bruce Rappaport School of Medicine, Technion Institute of Technology, Department of internal medicine H, Haifa, Israel, 2Rambam Health Care Campus & Bruce Rappaport School of Medicine, Technion Institute of Technology, Department of Epidimiology, Haifa, Israel, 3Chaim Sheba Medical Center, Gastroenterology, Ramat Gan, Israel, 4Tel Aviv Sourasky Medical Center, affiliated to the Sackler Faculty of Medicine, Tel Aviv University, IBD Center, Department of Gastroenterology and Liver Diseases, Tel Aviv, Israel, 5Rambam Health Care Campus & Bruce Rappaport School of Medicine, Technion Institute of Technology, Department of Gastroenterology, Haifa, Israel